Carl Uli Bialucha

1.2k total citations
16 papers, 861 citations indexed

About

Carl Uli Bialucha is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Carl Uli Bialucha has authored 16 papers receiving a total of 861 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Carl Uli Bialucha's work include HER2/EGFR in Cancer Research (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). Carl Uli Bialucha is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). Carl Uli Bialucha collaborates with scholars based in United States, United Kingdom and Japan. Carl Uli Bialucha's co-authors include Yasuyuki Fujita, Catherine Hogan, Stephan M. Feller, Walter Birchmeier, Norberto Serpente, Patricia Cogram, Vania Braga, Scott W. Lowe, Yasuyuki Fujita and Emma C. Ferber and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Cell Biology and Molecular and Cellular Biology.

In The Last Decade

Carl Uli Bialucha

16 papers receiving 844 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Carl Uli Bialucha United States 11 589 284 243 95 80 16 861
Chanan Rubin Israel 9 894 1.5× 187 0.7× 265 1.1× 106 1.1× 80 1.0× 9 1.1k
Michael V. Grandal Denmark 12 564 1.0× 261 0.9× 365 1.5× 57 0.6× 122 1.5× 13 897
Masaki Morishige Japan 10 436 0.7× 275 1.0× 132 0.5× 96 1.0× 87 1.1× 21 722
Julie Loader United Kingdom 10 591 1.0× 135 0.5× 222 0.9× 139 1.5× 77 1.0× 12 845
Julie S. Di Martino United States 14 367 0.6× 285 1.0× 285 1.2× 184 1.9× 117 1.5× 21 861
Pegah Rouhi Sweden 12 590 1.0× 289 1.0× 210 0.9× 282 3.0× 91 1.1× 12 913
Faraz K. Mardakheh United Kingdom 17 687 1.2× 200 0.7× 184 0.8× 172 1.8× 69 0.9× 28 944
Virginie Sanguin‐Gendreau Canada 17 506 0.9× 142 0.5× 368 1.5× 148 1.6× 126 1.6× 24 820
Eva Nievergall Australia 10 479 0.8× 252 0.9× 176 0.7× 58 0.6× 80 1.0× 17 859
Steven Pennock United States 11 534 0.9× 235 0.8× 149 0.6× 46 0.5× 63 0.8× 16 849

Countries citing papers authored by Carl Uli Bialucha

Since Specialization
Citations

This map shows the geographic impact of Carl Uli Bialucha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Uli Bialucha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Uli Bialucha more than expected).

Fields of papers citing papers by Carl Uli Bialucha

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl Uli Bialucha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Uli Bialucha. The network helps show where Carl Uli Bialucha may publish in the future.

Co-authorship network of co-authors of Carl Uli Bialucha

This figure shows the co-authorship network connecting the top 25 collaborators of Carl Uli Bialucha. A scholar is included among the top collaborators of Carl Uli Bialucha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl Uli Bialucha. Carl Uli Bialucha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Bialucha, Carl Uli, Hanumantha Rao Madala, Manoussa Fanny, et al.. (2022). 841 XTX202, a tumor-selective protein-engineered IL-2, exhibited enhanced anti-tumor activity in combination with checkpoint inhibition in mice. Regular and Young Investigator Award Abstracts. A878–A878. 1 indexed citations
2.
Schöffski, Patrick, Nicole Concin, Cristina Suárez, et al.. (2021). A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. Oncology Research and Treatment. 44(10). 547–556. 19 indexed citations
3.
Karpov, Alexei S., Tinya J. Abrams, Joseph A. D’Alessio, et al.. (2018). Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody–Drug Conjugates. ACS Medicinal Chemistry Letters. 9(8). 838–842. 29 indexed citations
4.
Collins, Scott D., Carl Uli Bialucha, Juliet Williams, & Hui Gao. (2017). Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates. Molecular & Cellular Oncology. 5(1). e1394422–e1394422. 1 indexed citations
5.
Bialucha, Carl Uli, Kathy L. Miller, Stuart W. Hicks, et al.. (2016). Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. mAbs. 8(3). 513–523. 17 indexed citations
6.
Ebbesen, Saya H., Maurizio Scaltriti, Carl Uli Bialucha, et al.. (2016). Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proceedings of the National Academy of Sciences. 113(11). 3030–3035. 56 indexed citations
7.
Garrett, Joan T., Cammie R. Sutton, Richard Kurupi, et al.. (2013). Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers. Cancer Research. 73(19). 6013–6023. 72 indexed citations
8.
Garrett, Joan T., Cammie R. Sutton, Carl Uli Bialucha, et al.. (2013). Abstract 5461: A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors .. Cancer Research. 73(8_Supplement). 5461–5461. 1 indexed citations
9.
Sheng, Qing, Huiqin Wang, Rita Das, et al.. (2013). Abstract 4261: Targeting HER3 and PI3K in head and neck squamous cancer cells.. Cancer Research. 73(8_Supplement). 4261–4261. 5 indexed citations
10.
Garner, Andrew P., Qing Sheng, Carl Uli Bialucha, et al.. (2012). Abstract 2733: LJM716: an anti-HER3 antibody that inhibits both HER2 and NRG driven tumor growth by trapping HER3 in the inactive conformation.. Cancer Research. 72(8_Supplement). 2733–2733. 6 indexed citations
11.
Tamori, Yoichiro, Carl Uli Bialucha, Aiguo Tian, et al.. (2010). Involvement of Lgl and Mahjong/VprBP in Cell Competition. PLoS Biology. 8(7). e1000422–e1000422. 138 indexed citations
12.
Bric, Anka, Cornelius Miething, Carl Uli Bialucha, et al.. (2009). Functional Identification of Tumor-Suppressor Genes through an In Vivo RNA Interference Screen in a Mouse Lymphoma Model. Cancer Cell. 16(4). 324–335. 140 indexed citations
13.
Dupré‐Crochet, Sophie, Angélica Figueroa, Catherine Hogan, et al.. (2007). Casein Kinase 1 Is a Novel Negative Regulator of E-Cadherin-Based Cell-Cell Contacts. Molecular and Cellular Biology. 27(10). 3804–3816. 74 indexed citations
14.
Bialucha, Carl Uli, Emma C. Ferber, Franck Pichaud, Sew‐Yeu Peak‐Chew, & Yasuyuki Fujita. (2007). p32 is a novel mammalian Lgl binding protein that enhances the activity of protein kinase Cζ and regulates cell polarity. The Journal of Cell Biology. 178(4). 575–581. 24 indexed citations
15.
Lawlor, Elizabeth R., Laura Soucek, Lamorna Brown Swigart, et al.. (2006). Reversible Kinetic Analysis of Myc Targets In vivo Provides Novel Insights into Myc-Mediated Tumorigenesis. Cancer Research. 66(9). 4591–4601. 60 indexed citations
16.
Hogan, Catherine, Norberto Serpente, Patricia Cogram, et al.. (2004). Rap1 Regulates the Formation of E-Cadherin-Based Cell-Cell Contacts. Molecular and Cellular Biology. 24(15). 6690–6700. 218 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chanan Rubin Breakdown of academic impact, for papers by Michael V. Grandal Breakdown of academic impact, for papers by Masaki Morishige Breakdown of academic impact, for papers by Julie Loader Breakdown of academic impact, for papers by Julie S. Di Martino Breakdown of academic impact, for papers by Pegah Rouhi Breakdown of academic impact, for papers by Faraz K. Mardakheh Breakdown of academic impact, for papers by Virginie Sanguin‐Gendreau Breakdown of academic impact, for papers by Eva Nievergall Breakdown of academic impact, for papers by Steven Pennock
Rankless by CCL
2026